SCHEMBL25909820

SCHEMBL25909820

Cc1ccccc1-c1cc2cnc(Cl)nc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 1/20 0.42
FGFR3 P22607 1/20 0.42
CYP19A1 P11511 1/20 0.40
RIPK2 O43353 2/20 0.40
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39
KDM5B Q9UGL1 1/20 0.39
NPY5R Q15761 1/20 0.39
RIPK1 Q13546 1/20 0.38
FFAR1 O14842 1/20 0.37
LCK P06239 1/20 0.37
KDR P35968 1/20 0.37
JAK3 P52333 1/20 0.37
MAPK14 Q16539 1/20 0.37
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20455601 0.79 CYP19A1 (0.42) FGFR2FGFR3CYP19A1RIPK2KDM5A
SCHEMBL29890560 0.79 CYP19A1 (0.42) FGFR2FGFR3CYP19A1RIPK2KDM5A
SCHEMBL17714318 0.78 RIPK2 (0.55) FGFR2FGFR3CYP19A1RIPK2KDM5A
SCHEMBL20455587 0.77 CYP19A1 (0.46) FGFR2FGFR3CYP19A1RIPK2KDM5A
SCHEMBL24071161 0.75 CDK5 (0.50) FGFR2FGFR3CYP19A1RIPK2KDM5A
SCHEMBL20470633 0.75 ADORA2A (0.49) FGFR2FGFR3CYP19A1KDM5AKDM4C
SCHEMBL2465423 0.74 ORAI1 (0.40) FGFR2FGFR3RIPK1FFAR1ABL1
SCHEMBL28277239 0.74 RIPK1 (0.68) NPY5RRIPK1CCNB2CDK1CCNB1
SCHEMBL3398994 0.72 TYRO3 (0.43) SMN1; SMN2ALDH1A1NFKB1NFKB2RELA
SCHEMBL27158570 0.69 CCNB2 (0.67) FGFR2FGFR3KDM5AKDM4CKDM5B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists SAIL BIOMEDICINES, INC. 2023-07-27 US disclosed
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists SAIL BIOMEDICINES, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234967-A1 Fused Azole Heterocycles as AHR Antagonists AHR, ARNT, AIPL1 FGFR2 899/4885FGFR3 375/4885CYP19A1 265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.